ライフサイエンスコーパス: hypercoagulability

1 e respiratory distress syndrome and systemic hypercoagulability.

2 flammation, of which a hallmark is increased hypercoagulability.

3 outside-in signaling, ultimately leading to hypercoagulability.

4 with increased thrombin generation, indicate hypercoagulability.

5 on and scalenectomy for SVT as those without hypercoagulability.

6 vein patency was similar to patients without hypercoagulability.

7 specially clear in those patients with known hypercoagulability.

8 he presence of any of the acquired causes of hypercoagulability.

9 ansplant candidates with Fabry's disease for hypercoagulability.

10 group, and comorbid conditions suggestive of hypercoagulability.

11 ignificant comorbid conditions suggestive of hypercoagulability.

12 Recurrent pregnancy loss may result from hypercoagulability.

13 ent decreases in endothelial cell injury and hypercoagulability.

14 sting of ascites, electrolyte imbalance, and hypercoagulability.

15 tivation and injury, platelet activation and hypercoagulability.

16 yper-inflammatory immune response; and last, hypercoagulability.

17 omorbidities, potentially due to an acquired hypercoagulability.

18 hronic kidney disease (CKD) commonly exhibit hypercoagulability.

19 ental health diagnoses (2.50, 2.04 to 3.04), hypercoagulability 1.47 (1.2 to 1.73), and cardiac rhyth

20 were infection (69%), dehydration (26%), and hypercoagulability (23%).

21 didates with Fabry's disease were tested for hypercoagulability, analyzed for HLA-type and ABO group,

22 rther supporting an independent link between hypercoagulability and cancer survival.

23 Hypercoagulability and cardiovascular pathology were onl

24 cell disease (SCD) contributes to a state of hypercoagulability and confers a risk of thromboembolic

25 latory ratios, 2.6 +/- 0.8) with evidence of hypercoagulability and fibrinolytic "shutdown".

26 thrombotic events are influenced by systemic hypercoagulability and fibrinolytic activity.

27 s with T2D had a much greater propensity for hypercoagulability and for amyloidogenesis, and that the

28 Acute lung injury is characterized by hypercoagulability and impaired fibrinolysis.

29 occurrence is significantly associated with hypercoagulability and impaired fibrinolysis.

30 risk involved subclinical-myocardial damage, hypercoagulability and increased inflammation, but not h

31 ibitor-1 (PAI-1) in mediating stress-induced hypercoagulability and thrombosis.

32 ing viral persistence, chronic inflammation, hypercoagulability, and autonomic dysfunction.

33 es with biomarkers of systemic inflammation, hypercoagulability, and comorbidities that are less prom

34 ysiological characteristics of inflammation, hypercoagulability, and endothelial injury.

35 naemia, compensatory haemopoietic expansion, hypercoagulability, and increased intestinal iron absorp

36 nduces platelet aggregation, correlates with hypercoagulability, and is associated with increased ris

37 The association between arch plaques and hypercoagulability, and its effect on the stroke risk, w

38 ial cells, plug the microvasculature, induce hypercoagulability, and promote infarct expansion.

39 er characterized by intravascular hemolysis, hypercoagulability, and relative bone marrow failure [1]

40 osis, complete reendothelialization, reduced hypercoagulability, and restoration of the vasodilatory

41 uding inflammation, endothelial dysfunction, hypercoagulability, and sympathetic hyperactivity.

42 osteocyte and/or endothelial cell apoptosis, hypercoagulability, and vasoconstriction of specific art

43 effectively improved neointimal hyperplasia, hypercoagulability, and vasoreactivity.

44 also showed that markers of inflammation and hypercoagulability are increased in this population.

45 linical evidence of vascular dysfunction and hypercoagulability as well as pulmonary vascular damage

46 mechanisms that apparently contribute to the hypercoagulability associated with cancer.

47 ted for traumatic injury or surgery; (3) had hypercoagulability at admission; or (4) received therape

48 kers and abnormal liver enzymes; infectious, hypercoagulability, autoimmune, cardiovascular, and neur

49 in one of the more common causes of acquired hypercoagulability, both in patients with systemic lupus

50 Patients with hypercoagulability do as well with first rib resection a

51 insufficiency or prolonged immobility), and hypercoagulability (due to cancer or pregnancy) are path

52 onic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropath

53 uld be used with caution in cases with known hypercoagulability, excessive bleeding in the setting of

54 edian platelet count nadir, 49 x 109/L), and hypercoagulability (greatly elevated D-dimer levels).

55 Numerous new factors associated with hypercoagulability have been described in the past few y

56 disease and a diagnostic workup for arterial hypercoagulability, however, these strategies are not li

57 omplex interplay of endothelial dysfunction, hypercoagulability, hypoxia, and immune complex depositi

58 Patients are tested for hypercoagulability if they present with a spontaneous cl

59 the possible value of quantifying indices of hypercoagulability in clinical practice.

60 normal platelet reactivity may contribute to hypercoagulability in COVID-19 and confirms the role tha

61 his study was to determine the prevalence of hypercoagulability in patients undergoing first rib rese

62 nctional inhibitors of ASMase may help treat hypercoagulability in patients with COVID-19.

63 n the predictive value of various markers of hypercoagulability in patients with heart failure, the a

64 Evaluation of inherited hypercoagulability in patients with venous thromboemboli

65 re associated with impaired fibrinolysis and hypercoagulability in subjects with normal glucose toler

66 Hypercoagulability in such women may therefore be due to

67 A major mechanism of hypercoagulability in the antiphospholipid syndrome (APS

68 s that autoantibodies directly contribute to hypercoagulability in the antiphospholipid syndrome (APS

69 This is supported by the presence of hypercoagulability, increased CD61 and CD62P on resting

70 Hypercoagulability increases risk of thrombi that cause

71 Finally, IdeS prevented thrombocytopenia and hypercoagulability induced by 5B9 with heparin in transg

72 Hypercoagulability is a potential underlying mechanism t

73 oexistence of large aortic plaques and blood hypercoagulability is associated with an increased risk

74 Although hypercoagulability is commonly associated with malignanc

75 The term "hypercoagulability" is used to describe patients who are

76 However, these patients also have a form of hypercoagulability, manifested primarily by high fibrino

77 Hypercoagulability may be a key mechanism for acute orga

78 whether these and other potential markers of hypercoagulability may help to identify cancer patients

79 Postarrest hypercoagulability of blood seems to yield to therapeuti

80 Thus, the effects of blood flow stasis, hypercoagulability of blood, and the characteristics of

81 The hypercoagulability of pregnancy is present as early as t

82 Our goal was to assess the effect of hypercoagulability on the risk of stroke in patients wit

83 ssociated with gene polymorphisms that cause hypercoagulability or increased platelet stickiness was

84 e majority, a recognized genetic tendency to hypercoagulability or platelet stickiness does not under

85 stroke (OR, 4.43; CI, 3.05-6.42; P < 0.001), hypercoagulability (OR, 2.90; CI, 1.56-5.39; P < 0.001),

86 ysm, hypertension, hyperlipidemia, diabetes, hypercoagulability, or hypermobile septum; and medicatio

87 an extensive laboratory thrombophilia (i.e., hypercoagulability) panel at the time of diagnosis in 14

88 Whether hypercoagulability predisposes for malignancy or the con

89 for all three scenarios were the presence of hypercoagulability, prior deep venous thrombosis, or a c

90 osis because of severe lung inflammation and hypercoagulability rather than thromboembolism.(C) RSNA,

91 enal transplant candidates were screened for hypercoagulability risk factors [HRF] (multiple arteriov

92 pectively detected in 10 study patients with hypercoagulability risk factors.

93 A hypercoagulability state has been reported as a major pa

94 Of the 136 patients diagnosed with a hypercoagulability state, 68.4% (93/136) had undergone t

95 by both an increased risk of bleeding and a hypercoagulability state, as seen in the patient populat

96 In cancer, neutrophils contribute to a hypercoagulability state, which promotes tumor growth an

97 rge aortic plaques are associated with blood hypercoagulability, suggesting a role for coagulation ac

98 nduced thrombocytopenia leads to an acquired hypercoagulability syndrome.

99 , patients were retrospectively reviewed for hypercoagulability testing and clinical outcomes.

100 Of those who had not undergone hypercoagulability testing, 5.9% (43/731) were diagnosed

101 Coagulopathy manifested predominantly as hypercoagulability that correlated directly with systemi

102 ) are associated with a clinical syndrome of hypercoagulability, thrombocytopenia, and fetal loss.

103 ction, blood stasis from LV dysfunction, and hypercoagulability triggered by inflammation, with each

104 Pregnancy is an example of Virchow's triad: hypercoagulability, venous stasis, and vascular damage;

105 The main reason for the increased risk is hypercoagulability, which has likely evolved to protect

106 Their relationship with blood hypercoagulability, which might enhance their embolic po

107 by warfarin fails to block cancer-associated hypercoagulability while nonetheless contributing to sev